Literature DB >> 23248247

Tumor assessment criteria in phase I trials: beyond RECIST.

Antonin Levy, Antoine Hollebecque, Charles Ferté, Serge Koscielny, Mariana Fernandez, Jean-Charles Soria, Christophe Massard.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23248247     DOI： 10.1200/JCO.2012.46.2184

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  Diffusion MRI of cancer: From low to high b-values.

Authors:  Lei Tang; Xiaohong Joe Zhou
Journal:  J Magn Reson Imaging       Date:  2018-10-12       Impact factor: 4.813

2.  Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Authors:  Mizuki Nishino; Satoshi Wakai; Tomoyuki Hida; Suzanne E Dahlberg; Masahiro Ozaki; Hiroto Hatabu; Hisashi Tachizaki; Bruce E Johnson
Journal:  Eur J Radiol       Date:  2018-10-23       Impact factor: 3.528

3.  Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib.

Authors:  Mizuki Nishino; Tomoyuki Hida; Sasha Kravets; Suzanne E Dahlberg; Christine A Lydon; Hiroto Hatabu; Bruce E Johnson; Mark M Awad
Journal:  Eur J Radiol Open       Date:  2020-01-28

Review 4.  Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.

Authors:  Rodrigo Dienstmann; Jordi Rodon; Josep Tabernero
Journal:  Mol Oncol       Date:  2014-07-15       Impact factor: 6.603

5.  Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Stephanie Cardarella; David M Jackman; Michael S Rabin; Nikhil H Ramaiya; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson
Journal:  Cancer       Date:  2013-08-06       Impact factor: 6.860

6.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Authors:  Charles Ferté; Marianna Fernandez; Antoine Hollebecque; Serge Koscielny; Antonin Levy; Christophe Massard; Rastislav Balheda; Brian Bot; Carlos Gomez-Roca; Clarisse Dromain; Samy Ammari; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.